Roche‌ ‌announced the expansion of its collaboration with the U.S. Centers for Disease Control and Prevention (CDC) to strengthen laboratory capabilities in countries greatly affected by the HIV and TB epidemics. Through the implementation of a public-private partnership, named “Lab Networks for Health,” Roche and the CDC will seek to improve HIV and TB prevention, detection and treatment outcomes in select countries of Africa, Eastern Europe, Central Asia and the Western Hemisphere (e.g., Latin America, Central America and Caribbean regions).

-- Almost half of the world’s population has no or limited access to diagnostics

-- This situation is especially acute in low- and middle-income countries (LMICs) where diagnostics plays a critical role for treating and containing the spread of infectious diseases such as Tuberculosis (TB) and HIV

-- New partnership between Roche and the Global Fund supports low- and middle-income countries in broadening access to diagnostics, helping millions of previously undiagnosed people with TB and HIV get diagnosed and eventually treated

-- Access to innovative diagnostic solutions will contribute to the World Health Organization’s infectious disease elimination goals
-- Improving access to reliable diagnostics for disease management in countries with the highest burden
-- Early detection of infectious diseases with diagnostics helps clinicians save lives

-- New tests on cobas 6800/8800 systems provide clinicians information to help speed treatment and reduce the spread of infection
-- Rising challenge of drug resistance compounds the tuberculosis global health crisis
-- Mycobacteria test menu allows detection of tuberculosis, drug resistant tuberculosis and nontuberculous mycobacteria infections from single patient sample